BiotechTube
Syna Therapeutics

Syna Therapeutics

Barcelona, Spain· Est.
synatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Syna Therapeutics is a Barcelona-based joint venture between pharmaceutical manufacturer Reig Jofre and biotech developer LeanBio, established to capitalize on the global biosimilars market. The company combines LeanBio's R&D platforms with Reig Jofre's industrial-scale manufacturing capabilities for injectable and lyophilized products. A key milestone is an exclusive global licensing agreement with Intas Pharmaceuticals for its lead hematology biosimilar, LB-0702, with clinical trials slated for 2023. Syna's strategy is to develop a pipeline of biosimilars aimed at reducing healthcare costs while treating serious chronic illnesses.

HematologyOncology

Technology Platform

Integrated platform combining LeanBio's biosimilar R&D capabilities with Reig Jofre's large-scale GMP manufacturing plant for sterile injectables and lyophilized products.

Opportunities

The global biosimilars market offers high growth (40% annually in EU until 2021) driven by patent expiries and cost-containment pressures in healthcare.
Syna's partnership with Intas provides immediate access to a global commercial network in 85 countries.
The integrated model from development to manufacturing is a competitive advantage in de-risking production.

Risk Factors

High development and regulatory risk associated with demonstrating biosimilarity in upcoming clinical trials.
Commercial success is dependent on the execution capabilities of its partner, Intas, in a competitive market.
The company's near-term value is concentrated in a single lead asset, LB-0702.

Competitive Landscape

Syna competes in the crowded and competitive global biosimilars market against large, established generics/biosimilars companies (e.g., Sandoz, Biocon, Celltrion) and other biotech innovators. Its differentiation lies in its focused, integrated Spanish model and strategic partnership for commercialization, but it must compete on development speed, cost, and product quality.

More companies in Biologics / Biosimilars →More companies in Spain →